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The proliferation and activation of microglia, the resident macrophages in the brain,
is a hallmark of many neurodegenerative diseases such as Alzheimer’s disease (AD)
and prion disease. Colony stimulating factor 1 receptor (CSF1R) is critically involved
in regulating microglial proliferation, and CSF1R blocking strategies have been recently
used to modulate microglia in neurodegenerative diseases. However, CSF1R is broadly
expressed by many cell types and the impact of its inhibition on the innate immune
system is still unclear. CSF1R can be activated by two independent ligands, CSF-1 and
interleukin 34 (IL-34). Recently, it has been reported that microglia development and
maintenance depend on IL-34 signaling. In this study, we evaluate the inhibition of IL-34
as a novel strategy to reduce microglial proliferation in the ME7 model of prion disease.
Selective inhibition of IL-34 showed no effects on peripheral macrophage populations in
healthy mice, avoiding the side effects observed after CSF1R inhibition on the systemic
compartment. However, we observed a reduction in microglial proliferation after IL-34
inhibition in prion-diseased mice, indicating that microglia could be more specifically
targeted by reducing IL-34. Overall, our results highlight the challenges of targeting the
CSF1R/IL34 axis in the systemic and central compartments, important for framing any
therapeutic effort to tackle microglia/macrophage numbers during brain disease.
Keywords: CSF1R (colony-stimulating factor 1 receptor), prion disease, tissue-resident macrophage, chronic
neurodegeneration, proliferation
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INTRODUCTION
Neuroinflammation is a critical component of neurodegenerative
diseases, including Alzheimer’s disease (AD), Parkinson’s disease
(PD), or prion diseases. The neuroinflammatory process is
characterized by a robust activation of the innate immune
system, with an increase in the number of microglial cells
associated with an activated and phagocytic phenotype (1–
3). Experimental models of prion disease present several
shared features of neurodegenerative diseases including protein
misfolding, progressive synaptic degeneration followed by loss of
neurons, microglial activation, and production of inflammatory
cytokines and chemokines (4).
The contribution of local proliferation of microglia, regulated
by the activation of the colony stimulating factor 1 receptor
(CSF1R), has been shown as a disease-modifying mechanism
during the progression of the ME7 prion model of progressive
chronic neurodegeneration (5). Similarly, a prolonged inhibition
of the tyrosine kinase activity of CSF1R blocks microglial
proliferation and prevents synaptic degeneration, ameliorating
disease progression, in the APP/PS1 model (6), the 3xTg
model (7), and the 5xFAD model (8, 9) of AD-like pathology.
More recently, our group has validated this disease-modifying
mechanism in the P301S mouse of tauopathy, demonstrating
that inhibition of CSF1R is effective in repolarising microglia
to a homeostatic phenotype, preventing neuronal degeneration
(10). In recent years, the therapeutic potential of blocking
antibodies and small molecule CSF1R kinase inhibitors has been
demonstrated in inflammatory diseases, neurological disorders,
bone diseases, and cancer, with some candidates currently in
clinical phase testing (11–13). However, the broader impact of
this approach on the innate immune system remains unclear.
CSF1R is expressed by cells of the myeloid lineage (14) and
therefore it is anticipated that the inhibition of CSF1R would
not only affect microglia, but also have potential on-target
effects in circulating and tissue-resident myeloid populations,
with a possible downstream immunosuppressive effect. CSF1R
can be activated by two independent ligands with high affinity,
the colony stimulating factor 1 (CSF-1) (15) and the recently
identified interleukin 34 (IL-34) (16). A potential avenue to
block this pathway more selectively is the specific modulation
of the binding of its ligands, to increase tissue specificity and
reduce side effects. Both ligands have been shown to promote
microglial proliferation (5) but also show a differential temporal
and spatial pattern of expression. Whereas CSF-1 is broadly
expressed (spleen, lymph nodes, cortex, bone marrow, amongst
others), the expression of IL-34 is restricted to a few tissues,
predominantly produced in the skin and the brain, with minimal
overlap with the CSF-1 expression pattern (17, 18). Interestingly,
mice lacking IL-34 (Il34LacZ) displayed a marked reduction of
Langerhans cells in the skin and microglial cells in the brain,
whereas other tissue macrophages were unaffected, showing that
IL-34 specifically controls the development and maintenance of
these populations (19, 20).
Since IL-34 has been shown to be a tissue-restricted ligand of
CSF1R, and it is crucial for the differentiation and maintenance
of microglial cells in the brain, we aimed to investigate whether
IL-34 inhibition could be used as a selective approach to reduce
microglial proliferation during chronic neurodegeneration with
minimal effects on other tissue-resident myeloid populations.
Here, we first describe the effects of the selective inhibition of IL-
34, compared to CSF1R inhibition, on different tissue-resident
populations in healthy mice, supporting tissue-selectivity of IL-
34. We also demonstrate that IL-34 inhibition decreases the
proliferation of microglial cells in the ME7 prion model, showing
that IL-34 is involved in the regulation of microglial proliferation
and supporting that the inhibition of this cytokine could be used
as a more selective approach to modulate microglial proliferation
in neurodegenerative diseases.
METHODS
In vitro Assessment of CSF1R
Phosphorylation
The N13 murine microglia cell line (21) was cultured in
Dulbecco’s modified Eagle’s medium (DMEM, Thermo Fisher
Scientific), supplemented with 10% fetal bovine serum and
50 U/mL penicillin/ streptomycin (Thermo Fisher Scientific).
Cells were maintained in T75 flasks at 37◦C in a 5% CO2
humidified atmosphere. Cells were plated at a density of 2
× 105 cells/cm2 in 6-well-plates and cultured overnight to
allow adherence. Cells were plated at a density of 2 × 105
cells/cm2 in 6-well-plates and cultured overnight to allow
adherence. Cells were kept in serum-free medium for 4 h prior
to stimulation and then incubated for the indicated time points
(5 or 10min) with recombinant CSF-1 (50 or 100 ng/mL), IL-
34 (50 or 100 ng/mL) (R&D Systems) or LPS (1µg/mL) as a
negative control for CSF1R pathway activation (22, 23), after
which cells were immediately lysed in RIPA buffer (Thermo
Fisher Scientific), supplemented with protease and phosphatase
inhibitor cocktails (Roche, Thermo Fisher Scientific). Protein
lysates were concentrated using Microcon-10kDa Centrifugal
Filter Units (Merck Millipore), according to manufacturer’s
instructions and protein concentration was determined using the
Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). Protein
lysates were subjected to SDS-PAGE and Western blot.
In vitro Assessment of IL-34 Neutralizing
Antibodies Using CellTiter Glo
Mouse myelogenous leukemia (M-NFS-60) cells were CSF-
1 (R&D systems, 216-MC/CF) starved for 24 h. In white
clear bottom 96-well-plates 10 µL IL-34 antibody (mouse
monoclonal IgG2A (v1.1 manufactured by Genscript, (24, 25)),
rat monoclonal IgG2A (MAB5195, R&D Systems) and sheep
polyclonal IgG (AF5195, R&D Systems) and 10µL IL-34 stimulus
(R&D systems, 5195-ML-CF) were incubated at 37◦C for 30min
before 80 µL M-NFS-60 cells (103 cells/well) were added.
After two days incubation at 37◦C cell viability was assessed
using CellTiterGlo (Promega, G7570) following manufacturer’s
instructions. Hundred microliter reconstituted CellTiterGlo was
added per well, plates were shaken for 2min and incubated at
room temperature for 10min before luminescence was read.
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Experimental Model of Prion Disease and
Pharmacological Treatments
C57BL/6Jmice (Harlan laboratories) and c-fms-eGFP (macgreen)
mice (26), characterized by eGFP expression under the c-
fms (CSF1R) promoter, were bred and maintained in local
facilities. Mice were housed in groups of 4–10, under a 12 h
light/12 h dark cycle at 21◦C, with food and water ad libitum.
To induce prion disease 6 weeks old C57BL/6J or macgreen
mice were anesthetized with a ketamine/xylazine mixture (85
and 13 mg/kg), and 1 µL of ME7-derived (ME7 group)
brain homogenate (10% w/v) was injected stereotaxically and
bilaterally at the dorsal hippocampus, coordinates from bregma:
anteroposterior, −2.0mm; lateral, ±1.7mm; depth, −1.6mm.
Naïve animals were used as controls. All procedures were
performed in accordance with U.K. Home Office licensing.
Group sizes were defined after performing power calculations,
in order to achieve a significant difference of p < 0.05, in light
of a retrospective analysis of our previous published results,
to reach a power between 0.80 and 0.90, depending on the
specific experimental conditions. The effect size was calculated
taking into consideration the strength of association between
the variables, the sensitivity, and the variation of any dependent
variable. The calculations are the customary ones based on
normal distributions.
For chronic treatment of healthy mice, rat monoclonal
CSF1R-blocking antibodies (BE0213, Bio X Cell) and rat
monoclonal IL-34 antibodies (MAB5195, R&D Systems) were
diluted in PBS, pH 7.4 and administered by intraperitoneal
injections 3 times a week for 3 weeks at a dose of 250
µg per injection. For chronic treatment in ME7 prion mice,
mouse monoclonal IL-34 IgG2A (24) was administered biweekly
for 4 weeks at a dose of 60 mg/kg, starting 12 weeks
after prion inoculation. For acute treatment in ME7 prion
mice, 1 µg of mouse or human-specific IL-34 neutralizing
antibody (sheep polyclonal IgG, AF5195, or AF5265, R&D
Systems) was stereotaxically and bilaterally injected into the
dorsal hippocampus, coordinates from bregma: anteroposterior,
?2.0mm; lateral, ±1.7mm; depth, ?1.6mm, 12 weeks after
induction of prion disease. Mice received daily intraperitoneal
BrdU injections (7.5 mg/mL, 0.1 mL/10 g weight in sterile saline;
Sigma-Aldrich) and were sacrificed 1 week after intracerebral
antibody administration. Weight of the mice was monitored
in all experiments, and no differences were observed between
treated and untreated groups. All the experimental groups
were randomized to avoid gender and cage effects, and all the
experiments were performed double-blinded.
Histology
Mice were terminally anesthetized with an overdose of sodium
pentobarbital and transcardially perfused with heparinised 0.9%
saline. Brain and peripheral organs (liver, kidney, and spleen)
were fixed in 4% paraformaldehyde overnight and immersed
in 30% sucrose in PBS for at least 24 h. Tissue was cut in
serial sections (35µm thick, coronal sections of the brain) with
a cryostat (Leica) and stored free-floating in cryoprotectant
solution [30% sucrose, 30% ethylene glycol, 1% Polyvinyl-
pyrrolidone (PVP-40) in 0.1M PB, pH 7.4] at −20◦C. For
histological analysis of peripheral organs, 4–6 sections from
each organ were randomly selected. For analysis of cortex,
hippocampal CA1 and dentate gyrus, every 6th systematically
sampled section, spanning the entire area of the hippocampus
and totalling 6–9 sections were used for quantification. Tissue
sections taken from macgreen mice were directly mounted
on slides with Mowiol/DABCO (Sigma-Aldrich) mixture.
Immunohistochemistry of brain sections from C57BL/6J mice
was performed as previously described (5). Briefly, sections were
subjected to DNA denaturation with 2N HCl (30min, 37◦C),
followed by incubation with 5% normal serum and 5% BSA in
PBS to block non-specific binding. After rinses with PBS-0.1%
Tween 20 (PBST), sections were incubated overnight at 4◦C
with rabbit anti-Iba1 (Wako, 019-19741) and anti-BrdU (Biorad,
MCA2060). After washes with PBST, sections were incubated
with host-specific Alexa 488- and 568-conjugated secondary
antibodies (Invitrogen). Brain sections and sections of peripheral
organs from macgreen mice mounted with Mowiol/DABCO
were imaged with a Leica DM5000B microscope coupled to
a Leica DFC300FX camera. Iba1-positive, BrdU/Iba1 double
positive and eGFP-positive cells in brain and organs of macgreen
mice were counted using the cell counter tool of the ImageJ
software and cell number was normalized to the quantified area.
Analysis of Skin-Resident Langerhans
Cells
Ears were fixed in 4% paraformaldehyde overnight and then
stored in PBS. The ears were split into dorsal and ventral halves
and each pair was mounted on slide under coverslip mounted
in Vectashield anti-fade mounting medium. For each half ear,
5 fields were chosen at random and 0.9-µm thick sections were
collected on a LSM700 confocal microscope (Zeiss) using settings
for eGFP fluorescence with a 40 × objective. For each field a
z-stack was taken to cover the full thickness of the Langerhans
cells layer-typically 5–100 images depending on the flatness of
the ear. Cell volume and number were measured using Volocity
software (Quorum Technologies). Cells were identified as those
with a GFP intensity >2SD from the mean image intensity. Non-
cellular objects<200 or>5,000µm3 were excluded. Objects with
a long axis >100µm were also excluded-this eliminated most
auto-fluorescent hairs in the z stacks. Each image was checked
manually to remove cell doublets and unexcluded hair profiles.
Flow Cytometric Analysis of Brain and
Blood Samples
Mice were terminally anesthetized with an overdose of sodium
pentobarbital and transcardially perfused with heparinised 0.9%
saline. Brain hemispheres were harvested in PBS with 2% FCS
and 2mM EDTA (FACS buffer) and mechanically triturated and
enzymatically dissociated using the Neural Tissue Dissociation
Kit (P) (Miltenyi), according to manufacturer’s instructions.
Samples were passed through a cell strainer of 70µmmesh (BD2
Falcon) with FACS buffer, and centrifuged at 500 × g for 10min
at 4◦C. After the second wash, cells were re-suspended in 37%
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Percoll (GE Healthcare) and centrifuged at 500× g for 30min at
18◦C. The supernatant and myelin layers were discarded, and the
cell pellet enriched with mononuclear cells was resuspended in
FACS buffer. Blood samples were harvested by cardiac puncture
and collected in EDTA-coated tubes. Brain cells and blood
samples were split in several tubes and immunostained. Primary
antibody labeling was performed for 1 h at 4◦C, using the
following antibodies: rat-anti-mouse CD11b (BD Biosciences,
clone M1/70), rat-anti-mouse CD45 (Biolegend, clone 30-F11)
and rat-anti-mouse Ly6C (BD Biosciences, clone AL-21) and
Fixable Viability Dye eFluorTM 450 (eBioscience). Moreover,
unstained cells and isotype-matched control samples were used
to control for autofluorescence and non-specific binding of
antibodies. After staining, erythrocytes in blood samples were
lysed in RBC lysis buffer (eBioscience). Cells were washed and
resuspended in FACS buffer. Samples were run on a BD FACS
Aria Flow cytometer, recording 100,000 events per sample. Data
was analyzed using FlowJo software.
SDS-PAGE and Western Blot
Frozen brain samples and peripheral organs were homogenized
in T-PERTM Tissue Protein Extraction Reagent (Thermo Fisher),
N13 cells were lysed in RIPA buffer (Thermo Scientific),
supplemented with protease inhibitors (EASYpack, Roche) and
phosphatase inhibitors (PhosSTOP, Roche). Homogenates were
centrifuged at 13,000 rpm and the supernatant was collected.
Protein was quantified using BCA assay (Thermo Fisher)
following the manufacturer’s instructions.
40 µg protein of N13 cell lysates was loaded to 7.5% Mini-
PROTEAN R© TGX Stain-FreeTM Protein Gels (BioRad) and
transferred to nitrocellulose membrane using the Trans-Blot R©
TurboTM RTA Mini Transfer Kit (BioRad). After blocking with
5% BSA in TBS/0.1% Tween20, membranes were incubated with
a combination of rabbit polyclonal antibodies against phospho-
M-CSF receptor (Tyr546, Tyr708, Tyr723, and Tyr923, Cell
signaling), phospho-AKT (Ser473, Cell signaling), or phospho-
p44/42 MAPK (Erk1/2) (Thr202/Tyr204, Cell signaling) over
night at 4◦C. Membranes were washed in TBS and further
incubated with an HRP-labeled anti-rabbit IgG (BioRad) for
2 h at room temperature. Membranes were incubated with
the SuperSignalTM West Pico Chemiluminescent Substrate
(Thermo Fisher Scientific) and signal was detected on the
ChemiDoc Imaging System (BioRad). Membranes were stripped
using the RestoreTM Western Blot Stripping Buffer (Thermo
Fisher Scientific) and reprobed with mouse monoclonal CSF-
1R antibody (D-8, Santa Cruz Biotechnology), anti-AKT
(Cell signaling), or anti-ERK1/ERK2 antibody (9B3, abcam),
followed by HRP-labeled anti-mouse or anti-rabbit IgG antibody
(BioRad). Intensity of protein bands was quantified using
Adobe Photoshop.
Elisa
NuncMaxiSorpTM flat-bottom 96-well-plates (Thermo Scientific)
were coated with F(ab’)2 fragment anti-rat or anti-mouse
IgG (H+L) (Jackson ImmunoResearch) overnight. Plates were
washed with PBS + 0.05% Tween20 and incubated with
blocking buffer (PBS containing 0.05% Tween20 and 1% BSA)
to block non-specific binding sites. Plasma samples or tissue
lysates diluted in blocking buffer were incubated for 2 h or
overnight. A standard was generated using respective anti-
IL-34 or anti-CSF1R antibodies that were used for in vivo
treatment. After washing, plates were incubated with peroxidase-
conjugated anti-rat or anti-mouse Fcγ subclass 2a-specific IgG
(Jackson ImmunoResearch) for 2 h, then washed and incubated
with 1-StepTM Ultra TMB-ELISA Substrate Solution (Thermo
Scientific). The reaction was stopped with 2N H2SO4 and the
signal was measured on a plate reader at 450 nm.
CSF-1 and IL-34 in plasma or brain were measured by
commercially available immunoassays (R&D systems), according
to manufacturer’s instructions.
Statistics
Data are shown as mean ± SEM and were analyzed using
the GraphPad Prism 6 software package (GraphPad Software),
using two-way ANOVA with Tukey’s post-hoc test for multiple
comparisons, Student’s t-test or one-way ANOVA followed by
Tukey’s post-hoc test for multiple comparisons, as indicated.
Differences were considered significant at p < 0.05.
RESULTS
IL-34 Induces Activation of the CSF1R
Signaling Pathway and IL-34-Mediated Cell
Growth Can Be Inhibited Using
Neutralizing Antibodies
To investigate whether IL-34 activates the CSF1R pathway
in microglia, we stimulated a murine microglia cell line
(N13) with either IL-34 or with CSF-1 and analyzed tyrosine
phosphorylation of the receptor and downstream signaling
molecules ERK1/ERK2 and AKT. Stimulation with either IL-
34 or CSF-1 leads to increased phosphorylation of CSF1R
and downstream mediators, indicating that IL-34 binds to and
activates the CSF1R pathway, triggering downstream signaling
pathways related to survival and proliferation (Figure 1A). IL-
34-mediated growth of myelogenous leukemia cell line M-
NFS-60 can be inhibited by three different IL-34 neutralizing
antibodies, which were further used in this study and showed
similar potencies [mouse monoclonal v1.1 (25): IC50 0.43 nM, rat
monoclonal MAB5195: IC50 0.53 nM, sheep polyclonal AF5195:
IC50 2.05Nm] (Figure 1B), indicating that CSF1R-dependent
signaling can be modulated by IL-34 inhibition.
CSF1R- but Not IL-34 Antibody-Mediated
Inhibition Leads to a Reduction of
CSF1R+/Ly6Clo Blood Monocytes
To determine the effect of CSF1R vs. IL-34 blockade on blood
immune cells, macgreen mice were treated by intraperitoneal
injections of CSF1R- or IL-34- neutralizing antibodies
(monoclonal rat IgG2a, 250 µg per injection, 3 injections
per week), vehicle (PBS), or rat IgG2a isotype for 3 weeks
(Figure 2A). The use of macgreen mice allows to monitor the
abundance of CSF1R+ cells based on the csf1r-eGFP transgene
reporter expression. Measuring antibody titers in the plasma
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FIGURE 1 | Activation of the CSF1R signaling pathway by IL-34 and CSF-1 and inhibition of IL-34-mediated cell growth using IL-34 neutralizing antibodies. (A) N13
microglia cell line was stimulated with IL-34 (50 or 100 ng/mL), CSF-1 (50 or 100 ng/mL) or LPS (1µg/mL) for 5 or 10min. Cell lysates were subjected to Western
blotting which showed increased phosphorylation of CSF1R and downstream ERK1/2 and AKT after IL-34 and CSF-1 stimulation. (B) IL-34 neutralizing antibodies
used in this study (mouse monoclonal IgG2A [v1.1, (24)), rat monoclonal IgG2A (MAB5195, R&D Systems) and sheep polyclonal IgG (AF5195, R&D Systems)]
prevented IL-34-dependent cell growth of M-NFS-60 in a similar nanomolar range. n = 3, data shown represent mean ± SEM, two-way ANOVA followed by Tukey’s
multiple comparison test. *p < 0.05, **p < 0.01, ***p < 0.001, comparisons are stimulations vs. unstimulated control (C) for each time point.
following treatment using a rat IgG2a-specific ELISA showed
comparable levels of antibody in anti-IL-34 and anti-CSF1R
treated mice, while levels of isotype control were found to
be significantly higher (Figure 2B). Administration of CSF1R
antibodies, but not IL-34 antibodies, increased CSF-1 levels
in the plasma (Figure 2C), which has been described as an
indication of target engagement (27). Levels of IL-34 were found
to be low in the plasma at baseline (∼30 times lower than CSF-1
levels) and were increased after CSF1R antibody treatment
similar to CSF-1 levels, while IL-34 was undetectable after IL-34
antibody treatment (Figure 2D). Flow cytometric analysis of
blood immune cells demonstrated a significant decrease in
CSF1R+ monocytes after CSF1R antibody treatment, which,
although a slight trend toward a reduction in cell number can be
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FIGURE 2 | Effect of CSF1R- and IL-34 antibody treatment on blood immune cell compartment. (A) Macgreen mice were treated with anti-CSF1R or anti-IL-34 (both
rat monoclonal IgG2A) by intraperitoneal injections of 250 µg antibody 3x a week for 3 weeks. (B–D) Levels of rat IgG2a, CSF-1 and IL-34 were measured in blood
plasma after the treatment by ELISA, which showed increased IL-34 and CSF-1 levels after CSF1R- but not IL-34 blockade. (E) Flow cytometric analysis of CSF1R+
cells in the blood of anti-CSF1R- and anti-IL-34- treated mice demonstrated a significant reduction after CSF1R- but not IL-34 antibody treatment. Graphs indicate
(Continued)
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FIGURE 2 | respective cell numbers per 5 × 104 CD45+ cells. (F) Flow cytometry of eGFP+ Ly6Chi and eGFP+ Ly6Clo subpopulations of CSF1R-expressing cells in
the blood shows a reduction in Ly6Clo cells after anti-CSF1R treatment, while Ly6Chi cells were not affected. Graphs indicate respective cell numbers per 5 × 104
CD45+ cells. PBS n = 8, isotype n = 8, anti-CSF1R n = 8, anti-IL-34 n = 7, data shown represent mean ± SEM, two-way ANOVA followed by Tukey’s multiple
comparison test. *p < 0.05, **p < 0.01, ***p < 0.001.
observed, was not significant after IL-34 antibody administration
(Figure 2E, for gating strategy see Supplementary Figure 1).
Further analysis of CSF1R+ subpopulations showed that the
reduction in blood monocytes after CSF1R antibody treatment
is largely due to an effect on cells with high CSF1R expression
(eGFPhi) as opposed to cells with intermediate CSF1R expression
(eGFPint, Figure 2E). The anti-CSF1R-sensitive eGFPhi cells
have been previously identified as CD14+ CD16++ human non-
classical monocytes, while the eGFPint population constitutes the
CD14++ CD16+/− intermediate and classical monocytes (28),
equivalent to the murine non-classical Ly6Clo monocytes and
the classical Ly6Chi monocytes, respectively. In accordance with
an effect on eGFPhi cells, the non-classical Ly6Clo monocytes
were predominantly reduced after anti-CSF1R treatment, while
classical Ly6Chi were not affected (Figure 2F). Again, both
Ly6Chi and Ly6Clo populations were not significantly reduced
after IL-34 antibody administration. In contrast to blood immune
cells, CSF1R+ cells in the bone marrow were not affected by
either CSF1R or IL-34 antibody treatment, indicating that CSF1R
is not required for the differentiation of myeloid progenitors
in the marrow (Supplementary Figures 2A,B). Taken together,
these results indicate that the number of CSF1R+ monocytes in
the blood depends on CSF1R, and is less dependent on IL-34.
Systemic IL-34 Blockade Reduces
Epidermal Langerhans Cells, but Not
Macrophage Populations in Liver and
Kidney or Microglia in the Brain
We next aimed to determine the effect of IL-34 and CSF1R
antibody treatment on different populations of tissue-
resident macrophages. Measurement of rat IgG2a levels
in liver, kidney, spleen, and brain by ELISA showed equal
distribution of IL-34- and CSF1R- neutralizing antibodies
in each organ, with a distribution between different organs
from highest to lowest as follows: spleen > kidney > liver
> brain (Supplementary Figure 3). Administration of IL-34
neutralizing antibodies for 3 weeks did not change the number of
CSF1R+ macrophages in the liver and in the kidney (Figure 3A).
In contrast treatment with a CSF1R blocking antibody lead
to a pronounced reduction of macrophages in both organs,
demonstrating a 41% reduction in liver-resident macrophages
and a 85% reduction of macrophages in the kidney (Figure 3A).
Skin-resident CSF1R+ Langerhans cells, were significantly
decreased after treatment with either IL-34- or CSF1R blocking
antibodies (Figure 3A). This indicates that skin-resident
Langerhans cells depend on IL-34- mediated signaling through
CSF1R, while macrophages in liver and kidney are maintained
by IL-34- independent CSF1R signaling.
To find out whether IL-34 antibody treatment affects
microglia number in the brain we quantified the number
of CSF1R+ cells in the cerebral cortex, hippocampal CA1,
and dentate gyrus. Peripheral administration of CSF1R or IL-
34 blocking antibodies for 3 weeks did not overtly affect
the number of microglia in the brain, with only a small
reduction in the CA1 region of the hippocampus observed after
anti-IL-34 administration (Figure 3B). Since previous reports
showed that CSF1R inhibition using small molecule inhibitors
leads to a reduction in microglia (5), it is likely that we
did not reach optimal antibody penetration into the brain
with the administered dose of antibody to achieve sufficient
target engagement.
Chronic Systemic Administration of IL-34
Blocking Antibody Lacks Sufficient Central
Target Engagement, Not Modifying the
Microglial Population in ME7 Prion Mice
We next aimed to investigate whether chronic systemic IL-
34 antibody treatment would affect microglia numbers in
the ME7 prion mice, a model of neurodegeneration which
is characterized by a pronounced expansion of the microglia
population (5). Based on our previous observation showing a
lack of effect in the brain with 250 µg antibody per injection
(∼10 mg/kg, Figure 3B), we increased the administered dose to
60 mg/kg per injection (Figure 4A). After 4 weeks of biweekly
intraperitoneal injections of the antibody in prion diseased mice,
microglia populations were analyzed by flow cytometry and
histology. While ME7 prion mice showed increased numbers
of microglia compared to naïve animals, as assessed by flow
cytometry (CD45int CD11b+ cells) and histology (Csf1r-eGFP+
cells), there was no difference in microglia numbers in brains
of anti-IL-34 treated animals compared to control-treatment
(Figures 4B,C). The proportion of CD45hi CD11b+ cells was
not affected by disease or treatment, indicating no effect on
infiltration of peripheral myeloid cells into the brain (Figure 4B).
Levels of isotype and anti-IL-34 antibody were detectable in
plasma and brain using a mouse-IgG2a specific ELISA, which
revealed higher levels of isotype compared to IL-34 antibody
in both compartments, with a brain/plasma ratio of 0.165
for the isotype and 0.141 for the IL-34 antibody (Figure 4D).
CSF-1 levels in the brain were significantly increased in prion
mice compared to naïve mice, but unaffected by the anti-
IL34 treatment (Figure 4E). IL-34 levels were around 300 times
higher in the naïve brain than CSF-1 levels, but not changed in
the context of prion disease or after IL-34 antibody treatment
(Figure 4E). In order to determine whether the absence of
an effect of IL-34 antibody treatment on microglia numbers
could be due to insufficient target engagement, we developed
an ELISA to capture mouse IgG2a from brain lysates, followed
by detection of IL-34 molecules bound to captured IgG2a.
Using this assay we detected bound IL-34 exclusively in brain
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FIGURE 3 | Effect of CSF1R- and IL-34 antibody treatment on tissue macrophages. (A) Histological analysis of CSF1R-positive cells in liver and kidney shows a
reduction after anti-CSF1R treatment, but not after anti-IL-34 treatment. Skin Langerhans cells were significantly reduced after both CSF1R – and IL-34 blockade. (B)
Microglia in cortex, hippocampal CA1 and dentate gyrus were not majorly affected by CSF1R or IL-34 antibody administration. Scale bar 100µm. PBS n = 8, isotype
n = 8, anti-CSF1R n = 8, anti-IL-34 n = 7, data shown represent mean ± SEM, two-way ANOVA followed by Tukey’s multiple comparison test. *p < 0.05, **p < 0.01,
***p < 0.001.
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FIGURE 4 | Peripheral IL-34 antibody injections in ME7 prion mice did not affect microglia numbers. (A) Macgreen mice infected with prion disease were treated with
anti-IL-34 (mouse monoclonal IgG2A) by intraperitoneal injections at a dose of 60 mg/kg twice a week for 4 weeks. (B) Flow cytometric analysis of CSF1R-positive
cells in the brain of anti-IL-34- treated mice showed no effect on number of CD45int CD11b+ or CD45hi CD11b+ cells. Graphs indicate respective cell numbers per
105 living cells. (C) Histological analysis of CSF1R-positive cells in the cortical brain shows unchanged microglial numbers after anti-IL-34 treatment. (D) Levels of
mouse IgG2a were measured in blood plasma and brain lysates by ELISA, which showed higher levels of isotype than anti-IL-34. Values for tissue/plasma ratio are
indicated above bars. (E) CSF-1 and IL-34 were measured in brain lysates, showing no alterations of IL-34 and CSF-1 levels after anti-IL-34 administration.
(Continued)
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FIGURE 4 | (F) IL-34 bound to anti-IL34 in brain lysates were detected by ELISA, by coating plates with anti-mouse IgG2a to capture IL-34 antibodies present in
brain lysates and detecting IL-34 bound to IL-34 antibodies with an IL-34 specific detection antibody (R&D systems). Levels of IL-34 bound to IL-34 antibodies were
<15% from total IL-34 levels. Scale bar 100µm. n = 8 per group, data shown represent mean ± SEM, two-way ANOVA followed by Tukey’s multiple comparison
test. *p < 0.05, **p < 0.01, ***p < 0.001.
lysates of mice treated with IL-34 antibody, but not with isotype
or PBS (Figure 4F). The percentage of IL-34 bound to IL-34
antibody showed a dose dependent increase after 2 injections
in healthy mice, demonstrating increased target engagement
with increasing doses of IL-34 antibody (Figure 4F). However,
ME7 prion mice treated for 4 weeks with biweekly injections
of 60 mg/kg showed that only ∼13% of total IL-34 was bound
to the antibody, suggesting a low degree of target engagement
(Figure 4F).
Intracerebral Administration of IL-34
Blocking Antibodies Reduces Microglia
Proliferation in ME7 Prion Mice
Since we did not achieve a significant degree of target engagement
in the brain with peripheral antibody administration, we
aimed to determine whether administering the antibody
directly into the brain of prion mice could affect microglia
numbers. IL-34 antibodies were stereotactically injected into
the hippocampus 12 weeks after induction of prion disease,
a timepoint of pronounced microglia proliferation (5), and
brains were collected 1 week after injection (Figure 5A).
Analysis of cells double-positive for the proliferation marker
BrdU and Iba1, a marker of microglia/macrophages, showed
increased microglial proliferation and increased total number
of Iba1-positive cells in the hippocampus of prion mice
compared to naïve mice, while injection of a mouse-specific
IL-34 neutralizing antibody significantly reduced microglia
proliferation by about 50% (Figure 5B). Administration of
a human-specific IL-34 antibody did not have an effect on
microglia proliferation, possibly due to reduced homology
with mouse IL-34 [71% (16)]. Microglial proliferation was
higher in ME7 compared to ME7 mice treated with isotype,
probably due to the injection itself causing microgliosis
associated to the local injury, which naïve and untreated
ME7 mice did not receive. The reduction of microglial
proliferation however did not result in a reduction of total
microglia numbers after IL-34 antibody administration at the
analyzed timepoint, probably due to the acute and transient
nature of the intervention, which merely affected the small
proliferating sub-population of the total microglial population
(Figure 5B). The finding that microglia proliferation was locally
reduced after direct intracerebral injection provides proof-
of-concept that IL-34 is involved in regulating microglia
proliferation in the context of chronic neurodegeneration and
that IL-34 blockade could be used as a strategy to reduce
microglia proliferation.
DISCUSSION
In this study we explored the effect of inhibition of IL-
34 on blood monocytes, systemic tissue macrophages, and
microglia in health and neurodegenerative disease, modeled
by a murine model of prion disease. IL-34 is a tissue-specific
ligand of the CSF-1 receptor predominantly expressed in the
brain and in the skin and has been shown to be crucial
for the development and survival of microglia and epidermal
Langerhans cells (19, 20). We showed here that inhibition of
IL-34 does not affect monocytes and macrophage populations
in many peripheral tissues, with an exception of skin-resident
Langerhans cells. Even though we did not achieve sufficient target
engagement in the brain after peripheral administration of IL-34
blocking antibodies, we observed a local reduction of microglia
proliferation when injecting IL-34 antibodies directly into the
brain of mice infected with prion disease, indicating that IL-34
is involved in driving proliferation of microglia in the context of
neurodegenerative disease.
IL-34 and CSF-1 were shown to activate the CSF1R signaling
cascade in a similar manner (29) and have an overall similar
effect on human monocyte differentiation in vitro as shown
by transcriptional profiling and pathway analysis (30). We
have also found that the activation pattern of CSF1R and
downstream pathway components AKT and ERK1/2 induced by
IL-34 resembles the one induced by CSF-1 inmicroglia. Although
IL-34 and CSF-1 seem to similarly affect CSF1R activation and
macrophage differentiation, they have distinct tissue expression
pattern with limited spatial overlap (29). A more recent report
confirms the distinct spatial distribution of IL-34 and CSF-
1 in the brain parenchyma, however describes differential
transcriptional signatures in microglia exposed to CSF-1 and
IL-34, suggesting divergent effects of the two CSF1R ligands
on microglia phenotype that might account for the observed
differences in regional microglial transcriptional profiles (31).
In accordance with previous reports which showed that IL-34
is more widely expressed in the brain than CSF-1 (17, 19, 20),
we observed that overall levels of IL-34 protein are ∼300 times
higher than CSF-1, highlighting its predominant role in the brain.
However, we also observed that IL-34 levels did not further
increase in the brain of prion-diseased mice.
It was demonstrated previously that CSF1R inhibition using
tyrosine kinase inhibitors can be used as a strategy to decrease
microglia proliferation in neurodegenerative disease models,
which led to beneficial effects such as reduced neuronal loss
and behavioral deficits in mouse models of prion disease (5),
tau pathology (10), and Aβ pathology (7, 9). Long-term CSF1R
inhibition could potentially increase risk of infections and lead to
disturbance of tissue homeostasis due to the reduction of CSF1R-
dependent macrophage populations in multiple organs. In a
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FIGURE 5 | Intracerebral IL-34 antibody administration resulted in reduced microglia proliferation in ME7 prion mice. (A) Mice infected with prion disease received a
single intracerebral injection of mouse- or human-specific anti-IL-34 (sheep polyclonal IgG) and brains were analyzed 1 week later. (B) Histological analysis of
BrdU/Iba1-positive microglial cells in the cortex showed a reduction after treatment with a mouse-, but not with a human-specific antibody. Scale bar 100µm. Naïve n
= 6, ME7 n = 12, ME7 + isotype n = 10, ME7 + anti-mIL-34 n = 8, ME7 + anti-hIL-34 n = 7, data shown represent mean ± SEM, two-way ANOVA followed by
Tukey’s multiple comparison test. *p < 0.05, **p < 0.01, ***p < 0.001.
Listeria monocytogenes infection model, CSF-1/IL-34 blockade
or treatment with anti-CSF-1 alone increased susceptibility to
bacterial infection, although to a lower degree than anti-TNF
therapy (32). Interestingly, IL-34 blockade did not alter infection
susceptibility (32), indicating an immunosuppressive effect as
observed with CSF-1 blockade can be prevented with anti-IL-34
treatment. CSF1R antagonism also lead to higher susceptibility
of mice to lethal West Nile virus infection and lack of virologic
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control in both brain and periphery, highlighting the importance
of myeloid cells in restriction of viral replication and the
restimulation of antiviral T cells recruited to the CNS (33). On
the other hand, a CSF1R tyrosine kinase inhibitor showed a good
safety and tolerability profile in patients with rheumatoid arthritis
over a course of 3 months, causing only minor side effects
related to compromised Kupffer cell function (27), however the
long-term consequences of CSF1R pharmacological inhibition
are not well-understood. Other possible side-effects of long-term
CSF1R blockade might include disturbances of bone formation
and resorption as well as the function of pancreatic β cells (see
Martin-Estebane and Gomez-Nicola (34) for further discussion).
A potential way to circumvent affecting multiple macrophage
populations is to target IL-34, which is predominantly expressed
in the brain. We aimed to evaluate whether inhibition of this
more tissue-restricted ligand of CSF1R would cause a reduction
in microglia proliferation without having a major impact on
peripheral myeloid cell populations. In support of this strategy,
the administration of recombinant IL-34 into the brain caused
locally increased microglia proliferation similar to CSF-1 (5),
showing that IL-34 can induce proliferation of microglia in
the brain. In IL-34lacZ/lacZ mice which lack IL-34, microglial
numbers are strongly reduced in many brain regions such
as cortex, hippocampus and striatum (19, 20), indicating that
IL-34 is at least partially responsible for maintenance of the
population. Targeting IL-34 using an antibody-based approach,
we showed that specific inhibition of IL-34 was sufficient to
reduce microglia proliferation present in prion pathology, at
least when IL-34 was inhibited over a short period of time by
administration of IL-34 antibodies directly into the brain. This
finding suggests that IL-34 is partially involved in regulating
microglia proliferation in neurodegenerative disease. However, it
proved to be challenging in our study to target brain-intrinsic
IL-34 using systemically administered neutralizing antibodies
probably due to their poor brain penetrance which prevented
sufficient antibody titers to efficiently neutralize biological
function of IL-34 in the brain. Although two recent reports
showed a reduction in microglial numbers after peripheral
administration of IL-34-specific monoclonal antibodies at high
doses (32, 35), we did not observe a modulation of microglial
numbers after chronic systemic antibody treatment in healthy
mice or mice infected with prion disease. We found IL-34
to be ∼300 times higher in the brain than CSF-1, while
in the blood it was nearly absent. This high abundance of
IL-34 in the brain emphasizes the difficulty in efficiently
targeting this cytokine with neutralizing antibodies. Similarly,
peripheral administration of CSF1R blocking antibodies did
not lead to a reduction in microglia in cortex, dentate gyrus
and CA1. The fact that blocking CSF1R using small molecule
inhibitors resulted in pronounced depletion of microglia in
several mouse models (5, 7, 9, 10), further indicates that the
strategy applied in this study using blocking antibodies is not
favorable. Lin et al. and Easley-Neal et al. provide first proof
that manipulation of IL-34 can be used to modify the microglia
population in the gray matter of most brain regions (35)
and that this approach might be relevant in the context of
inflammatory diseases and cancer (32). We extend these findings
by showing that in a model of neurodegenerative disease, which
is characterized by a pronounced expansion of the microglia
population predominantly in the hippocampus, inhibition of
IL-34 leads to reduced microglial proliferation. In order to
provide further proof-of-concept that IL-34 inhibition can be
used to tackle neurodegenerative disease, it is inevitable to
apply other strategies which offer an improved brain penetrance
profile, ideally by using small molecule inhibitors, which to
date does not exist. By contrast, it was recently shown that
prion disease induced in IL-34lacZ/lacZ mice did not change the
number and activation of microglia and rather accelerated prion
disease progression (36). It is possible that in the genetically
modified mice with a constitutive loss of function of IL-
34, CSF-1 compensates for the absence of IL-34 and drives
proliferation through CSF1R to expand themicroglial population
in prion disease. It is also possible that during long term
anti-IL34 treatment, CSF-1 will take over the function of IL-
34 in maintaining and expanding the microglial population
during neurodegeneration, given that it is also increased during
disease. This possibility needs to be investigated in the future
using more suitable pharmacological strategies than peripheral
antibody administration.
Chronic inhibition of IL-34 did not majorly affect the
abundance of blood monocytes or tissue-resident macrophage
populations in liver and kidney, which were sensitive to CSF1R
blockade, suggesting IL-34- independentmechanisms of survival,
most likely through CSF-1. In line with this, a natural mutation
in the Csf-1 gene (op/op) caused a reduction in macrophages
in most tissues of the body (12), and long-term treatment
with a CSF1R-blocking antibody lead to a complete depletion
of Kupffer cells in the liver and prevented the development
of non-classical Ly6Clo monocytes in the blood (37), which
we likewise observed. It was previously shown, that genetic
deficiency of IL-34 resulted in decreased numbers of microglia
in most brain regions, while there was no effect on myeloid
cells in blood and bone marrow, Kupffer cells in the liver,
lung alveolar macrophages, and dendritic cells in the lung and
spleen (20). Similarly, a specific impact of IL-34 blockade on
Langerhans cell homeostasis, but not on liver, intestine and
kidney macrophages after IL-34 antibody administration has
been recently shown (32). We have also observed an effect
on Langerhans cells, which were reduced after both CSF1R-
and IL-34 antibody treatment, confirming a role of IL-34 in
regulating their survival as well as the efficacy of anti-IL-34
antibodies. Overall, sensitivity of macrophage populations to
IL-34 inhibition seems to be defined by the spatial expression
pattern of IL-34, which rarely overlaps with CSF-1 expression.
Thus, myeloid cells located in regions dominated by IL-34
expression can be targeted by inhibition of IL-34, which is
restricted to fewer organs, potentially reducing unwanted side
effects caused by therapeutic intervention targeting the CSF1R
pathway. We propose that IL-34 inhibition could be a viable
strategy to decrease proliferation of microglia in the context of
neurodegenerative disease, with restricted impact on peripheral
myeloid cells.
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Supplementary Figure 1 | Gating strategy used for flow cytometric analysis of
brain, blood, and bone marrow after CSF1R- and IL-34 antibody treatment.
Supplementary Figure 2 | Effect of CSF1R- and IL-34 antibody treatment on
bone marrow. Macgreen mice were treated with anti-CSF1R or anti-IL-34 (both rat
monoclonal IgG2A) by intraperitoneal injections of 250 µg antibody 3x a week for
3 weeks. (A) Flow cytometric analysis of CSF1R+ cells in the bone marrow of
anti-CSF1R- and anti-IL-34- treated mice did not result in significant alterations.
Graphs indicate respective cell numbers per 5 × 104 CD45+ cells. (B) Flow
cytometry of eGFP+ Ly6Chi and eGFP+ Ly6Clo subpopulations of
CSF1R-expressing cells in the bone marrow did not reveal any significant changes
due to the treatment. Graphs indicate respective cell numbers per 5 × 104 CD45+
cells. PBS n = 8, isotype n = 8, anti-CSF1R n = 8, anti-IL-34 n = 7, data shown
represent mean ± SEM, two-way ANOVA followed by Tukey’s multiple
comparison test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
Supplementary Figure 3 | Distribution of CSF1R- and IL-34 antibodies in
peripheral organs and brain. Macgreen mice were treated with anti-CSF1R or
anti-IL-34 (both rat monoclonal IgG2A) by intraperitoneal injections of 250 µg
antibody 3x a week for 3 weeks. Levels of rat IgG2a were measured in tissue
lysates of brain, liver, kidney and spleen after the treatment by ELISA, showing no
significant differences between anti-CSF1R and anti-IL-34 in individual organs.
Brain: PBS n = 8, isotype n = 8, anti-CSF1R n = 8, anti-IL-34 n = 7,
liver/kidney/spleen: PBS n = 4, isotype n = 4, anti-CSF1R n = 3, anti-IL-34 n = 4,
data shown represent mean ± SEM, two-way ANOVA followed by Tukey’s
multiple comparison test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
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